bioAffinity Technologies Announces 100% Increase In Sales For Its CyPath Lung Test For Lung Cancer

bioAffinity Technologies, Inc. (NASDAQ: BIAF) reported a more than 100% increase in sales of its CyPath® Lung test for lung cancer through Q3 2026 compared to the previous year. The number of ordering physicians rose by 89% year-over-year, and those who ordered the test in the prior year increased their utilization, leading to a 48% rise in sales volume. A total of over 1620 tests were delivered through Q3 2026, up from 775 tests in Q3 2025.